JBPHF.US Jacobio Pharmaceuticals Group Co. Ltd.

Healthcare Biotechnology USA Stocks
0.7552 USD
Close of Nov 14, 2026
0.5955 1.10
Market cap
USD 591M
P/E
8.4x
P/B
2.92x
ROE
-18.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is JBPHF.US undervalued?

Graham number
Price0.7552
Graham value0.7243
Premium4.3%

JBPHF.US trades 4.3% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Jacobio Pharmaceuticals Group Co. Ltd. fundamental analysis

No fundamental analysis for Jacobio Pharmaceuticals Group Co. Ltd. yet.

Jacobio Pharmaceuticals Group Co. Ltd. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Jacobio Pharmaceuticals Group Co. Ltd.

Jacobio Pharmaceuticals Group Co., Ltd., an investment holding company, engages in the in-house discovery and development of oncology therapies in the People's Republic of China. The company develops sitneprotafib (JAB-3312), an oral allosteric SHP2 inhibitor that is in a Phase III trial for non-small cell lung cancer (NSCLC); glecirasib (JAB-21822), a KRAS G12C allosteric inhibitor in Phase II trials for NSCLC, multi-tumor basket, and colorectal cancer; JAB-8263, a BET inhi…

Full company profile